Briobacept

Drug Profile

Briobacept

Alternative Names: BAFF-R protein therapeutic - Biogen Idec/Genentech; BLyS neutralizing molecule; BR3 Fc - Biogen Idec/Genentech

Latest Information Update: 31 May 2010

Price : $50

At a glance

  • Originator Biogen Idec; Genentech
  • Class Antirheumatics; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action B cell inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Rheumatoid arthritis; Sjogren's syndrome

Most Recent Events

  • 14 Jun 2008 Pharmacokinetics, pharmacodynamics and adverse events data from a trial in rheumatoid arthritis presented at the Annual European Congress of Rheumatology (EULAR-2008)
  • 29 Nov 2006 Data presented at the 70th Annual Scientific Meeting of the American College of Rheumatology(ACR-2006) added to the adverse events, pharmacokinetics, Rheumatic Disease pharmacodynamics and immunogenicity sections
  • 06 Jul 2006 Phase-II clinical trials in Sjogren's syndrome in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top